Beta Drugs Limited — Important, 12-03-2025: General Updates

Beta Drugs Ltd. has successfully passed resolutions through a postal ballot, leading to a rise in its authorized share capital from ₹10.5 crore to ₹11 crore. This increase will facilitate the planned issuance of bonus shares at a ratio of 1:20, capitalizing ₹51.6 lakh from reserves to reward shareholders. Additionally, the company has appointed Mrs. Monica Jain and Mr. Lalit Kumar Watts as Independent Directors for a five-year term each. Another noteworthy decision involves migrating its equity shares from the Emerge platform to the main boards of both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). This strategic move is expected to enhance liquidity and visibility for the company’s shares. Shareholders should consider this a positive development, as these initiatives could strengthen the company's market position and investor confidence.